Piramal Pharma Limited
PPLPHARMA · Pharma · NSE
₹168
Current Market Price
Fair Value (DCF)
₹89
Discount to FV
-46.8%
Updated just now
YieldIQ Score
20/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
35%
ROE
1.1%
Debt/Equity
0.60
WACC
10.5%
Market Cap
₹22,276 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
12.7%
Return on capital employed
EV / EBITDA
26.3×
Enterprise multiple
Debt / EBITDA
4.9×
Leverage vs earnings
Interest Coverage
2.0×
EBIT covers interest
Current Ratio
1.54×
Short-term liquidity
Asset Turnover
0.57×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹167.89
Bear case
Margin of Safety —
Implied upside -211.3%
Base case
Margin of Safety -728.0%
Implied upside -87.9%
Bull case
Margin of Safety -24.1%
Implied upside -19.4%
Ratio Trends
PPLPHARMA · last 4 annual periods
ROE
1.1%
ROCE
12.7%
Operating Margin
—
Debt / Equity
0.60×
PE
180.8×
EV / EBITDA
12.3×
Historical Financials
PPLPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹6472 Cr | ₹7032 Cr | ₹8106 Cr | ₹9151 Cr | ₹8869 Cr | +8.2% |
| EBITDA | ₹1260 Cr | ₹894 Cr | ₹1367 Cr | ₹1653 Cr | ₹996 Cr | -5.7% |
| EBIT | — | ₹170 Cr | ₹568 Cr | — | — | +35.3% |
| PAT | ₹376 Cr | ₹-186 Cr | ₹17.8 Cr | ₹91.1 Cr | ₹-326 Cr | — |
| EPS (diluted) | — | ₹-1.57 | ₹0.14 | — | — | — |
| CFO | ₹766 Cr | ₹484 Cr | ₹1005 Cr | ₹892 Cr | ₹1653 Cr | +21.2% |
| CapEx | ₹-890 Cr | ₹-965 Cr | ₹-712 Cr | ₹-664 Cr | ₹-890 Cr | — |
| FCF | ₹-123 Cr | ₹-481 Cr | ₹293 Cr | ₹228 Cr | ₹763 Cr | — |
| Total Assets | ₹12.8K Cr | ₹14.5K Cr | ₹15.3K Cr | ₹15.7K Cr | ₹18.0K Cr | +8.9% |
| Total Debt | ₹4128 Cr | ₹5637 Cr | ₹4710 Cr | ₹4856 Cr | ₹5675 Cr | +8.3% |
| Shareholders' Equity | ₹6697 Cr | ₹6774 Cr | ₹7911 Cr | ₹8125 Cr | ₹8163 Cr | +5.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
PPLPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 NEULANDLAB NEULANDLAB | — | — | Pending | 19.4% | — |
 GRANULES Granules India Limited | -63.4%-38.8% upside | 20 | Above Fair Value | 11.7% | 25.8× |
 APLLTD APLLTD | — | — | Pending | 11.9% | 19.3× |
 COHANCE COHANCE | — | — | Pending | 4.6% | — |
 JUBLPHARMA JUBLPHARMA | — | — | Pending | 5.6% | 32.5× |
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹0.25/sh
Last payout
2025-07-16
₹0.14
Peak payout
₹0.14
Trailing yield
0.08%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Piramal Pharma Limited (PPLPHARMA.NS) trades at 167.89 vs a model fair value of 89.34, a gap of -46.8%. Piotroski F-score: 4/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of PPLPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for PPLPHARMA →
Compare
Head-to-head with peers
Compare PPLPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse PPLPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.